Gouty Arthritis (Gout) – Global Clinical Trials Review, H2, 2021

Pages: 425 Published: November 23, 2021 Report Code: GDHC6799CTIDB

GlobalData’s clinical trial report provides data on the gouty arthritis clinical trial scenario. This report provides top-line data relating to the clinical trials on Gouty Arthritis (Gout). The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).

Gouty Arthritis (Gout) clinical trial report consists of 751 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 34, 62, 107, 367, and 4 respectively. Similarly, the trials with different status compile of Completed – 484, Ongoing – 93, Planned – 98, Suspended – 6, Terminated – 13, and Withdrawn – 57. Out of 484 completed trials 267 trials have achieved end points.

What are the market dynamics of the global gouty arthritis therapeutics clinical trials sector?

The number of gouty arthritis (gout) clinical trials conducted globally, has increased by 210% for the period 2016-2020. The average number of patients enrolled was highest in the year 2017. Companies were the leading sponsor for gouty arthritis clinical trials followed by institutions and governments. As of November 2021, out of 484 completed trials, 312 trials have results and over 86% of trials reached end points. There were 93 clinical trials in progress and 484 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 76. This was due to the lack of efficacy, safety, and lack of accrual of subjects. The majority of the trials were successfully completed. There were 93 clinical trials in progress of which over 30% were in Phase II study. There were 389 clinical trials in Phase I, of which 22 clinical trials were in progress for the time period 1995-2021.

What are the top regions and countries in the global gouty arthritis therapeutics clinical trials sector?

In total there were 751 clinical trials conducted on gouty arthritis (gout), as of November 2021, of these 361 clinical trials were in Asia-Pacific. More than 45% of the clinical trials were conducted in Asia-Pacific.

Asia-Pacific: As of November 2021, in the Asia-Pacific region, China has the highest number of gouty arthritis clinical trials followed by Japan, India, Australia, and Thailand.

Europe: Among the European countries, Russia has the highest number of gouty arthritis clinical trials, as of November 2021, followed by the UK, Germany, Poland, and Switzerland.

North America: In the country-wise analysis, the US has the highest number of gouty arthritis clinical trials, as of November 2021 followed by Canada and Mexico.

Middle East & Africa: South Africa has the highest number of gouty arthritis clinical trials, as of November 2021 followed by Israel, Iran, and Jordan.

Central and South America: Argentina has the highest number of gouty arthritis clinical trials, in the region followed by Colombia, Guatemala, Brazil, and Costa Rica.

G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, The US has the highest proportion of gouty arthritis to musculoskeletal disorders clinical trials as of November 2021. In total there were 307 clinical trials conducted on Gouty Arthritis (Gout), as of November 2021 in G7 Countries, of these 189 clinical trials were in the US. There were 20 clinical trials in progress and 216 trials are completed. The trials that are terminated/suspended or withdrawn accounted to 13. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of gouty arthritis to musculoskeletal disorders clinical trials as of November 2021. In total there were 301 clinical trials conducted on Gouty Arthritis (Gout), as of November 2021 in E7 Countries, of these 190 clinical trials were in China. There were 55 clinical trials in progress and 130 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 30.

Global gouty arthritis therapeutics clinical trials sector, by regions

Global gouty arthritis therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global gouty arthritis therapeutics clinical trials sector?

As of November 2021, AstraZeneca Plc has conducted the highest number of gouty arthritis (gout) clinical trials followed by Takeda Pharmaceutical Co Ltd. Other major players include Fuji Yakuhin Co Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Jiangsu Hengrui Medicine Co Ltd, PRACS Institute, Ltd. (Inactive), Teijin Ltd, CymaBay Therapeutics Inc, and Suzuken Co Ltd.

Global gouty arthritis therapeutics clinical trials sector, by key companies

Global gouty arthritis therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key countries China, The US, Russia, Japan, India, Australia, Canada, Thailand, New Zealand, and the UK
Key companies AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, Fuji Yakuhin Co Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Jiangsu Hengrui Medicine Co Ltd, PRACS Institute, Ltd. (Inactive), Teijin Ltd, CymaBay Therapeutics Inc, and Suzuken Co Ltd.

Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for un-accomplishment.
  • The report provides enrollment trends for the past five years.
  • Report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional, and country-level.

Key Players

AstraZeneca Plc

Takeda Pharmaceutical Co Ltd

Fuji Yakuhin Co Ltd

Sun Pharmaceutical Industries Ltd

Novartis AG

Jiangsu Hengrui Medicine Co Ltd

PRACS Institute, Ltd. (Inactive)

Teijin Ltd

CymaBay Therapeutics Inc

Suzuken Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Gouty Arthritis (Gout) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Source

List of Tables

List of Tables

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Region, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, North America, Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2021*

Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Gouty Arthritis (Gout) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

List of Figures

List of Figures

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Region (%), 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2021*

Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Gouty Arthritis (Gout) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2021*

Gouty Arthritis (Gout) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Phase (%), 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Gouty Arthritis (Gout) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Gouty Arthritis (Gout) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

GlobalData Methodology

Frequently Asked Questions

Enquire Before Buying
$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.